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A B S T R A C T   
A number of viruses transmitted by mosquitoes are well known to cause disease in both humans and horses, 
ranging from mild fevers to mortal neurological disease. A recently discovered connection between the alpha-
virus Sindbis virus (SINV) and neurological disease in horses in South Africa initiated this serological study in 
northern Europe, where the same genotype of SINV (SINV-I) is also highly endemic. We tested 171 serum 
samples, originally obtained from horses for other reasons from April to October 2019, for presence of SINV 
neutralising antibodies using a plaque reduction neutralisation test (PRNT). The serum from six horses reduced 
the plaque count more than 80%, and two out of these reduced the plaque count more than 90%. These horses 
were sampled in six different regions of Sweden, and included individuals sampled from April to August. This 
study shows that horses in Sweden have become infected with SINV and developed neutralising antibodies. 
Potential connections between infection and development of disease are important questions for future studies.   
1. Introduction 
Vector-borne infections have a great impact on both human and 
animal health worldwide [1]. The involvement of vertebrate host/s and 
invertebrate vectors contribute to the complex transmission patterns of 
these infections, and new knowledge is constantly being added. Some 
arthropod-borne viruses (arboviruses), transmitted by mosquitoes, are 
well known to cause disease in both humans and horses. These include 
the alphaviruses; Venezuelan equine encephalitic virus (VEEV). Eastern 
equine encephalitis virus (EEEV), Western equine encephalitis virus 
(WEEV), all present in North America, Gheta virus (GV) present pre-
dominantly in Asia, and Ross River virus (RRV) present in Australia, as 
well as the flaviviruses; West Nile virus (WNV) and Japanese encepha-
litis virus (JEV). Many of these viruses target the central nervous system 
in both humans and horses, with neurological symptoms as a conse-
quence, sometimes with mortal outcome [2–4] However, for RRV the 
symptoms in both horses and humans mainly come from inflammation 
of the joints, and GV is mainly associated with a febrile disease [5–7]. 
In northern Europe, the mosquito-borne alphavirus Sindbis virus 
(SINV) occasionally causes disease in humans, manifesting as fever and 
arthritis that could last for years [8,9]. SINV originates from Africa and 
has likely been introduced to northern Europe in the 1920s, potentially 
by migrating birds [10]. Recently, SINV has been linked to neurological 
disease in horses in South Africa [11]. In a study of 623 horses with 
unexplained febrile illness and/or neurological symptoms, eight horses 
tested positive for SINV RNA. Of the infected horses, one died from 
neurological disease, two survived neurological disease, and three 
recovered from a febrile illness. One of the horses also had mild colic and 
dysphagia from tongue paralysis. The remaining two horses also died, 
but was co-infected by WNV, thus the cause of death could not be 
established. 
SINV has a wide distribution and has been detected in mosquitoes 
and birds across the Old World. It has been categorised into six geno-
types, with genotype I (SINV-I) being associated to disease in humans 
[12]. SINV-I is distributed across Europe and Africa, but human cases are 
mainly reported from South Africa, Finland and Sweden [10]. Poten-
tially, ecological factors such as vector abundance and host population 
dynamics, are important determinators of transmission intensity and 
influence the geographical distribution of disease cases [13]. 
Like many of the above mentioned arbovirues, SINV is transmitted 
by mosquitoes mainly from the genus Culex, and utilizes passerine birds 
as its natural host. In Sweden, it is well established that SINV-I is 
frequently being transmitted during the summer months, based on in-
vestigations of virus detection in the mosquito population and serolog-
ical investigations of the passerine bird population [14,15]. If horses are 
susceptible to SINV-I and at risk of developing neurological disease, as 
been reported from South Africa, it is possible that northern European 
horses are also at risk of becoming infected with the virus. Since the link 
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between SINV and infection in horses is new, the aims of this investi-
gation were double: to initiate the study of SINV serology in horses, and 
to examine whether Swedish horses have been infected with SINV. 
2. Materials and methods 
In total, 171 serum samples from horses were used for testing the 
presence of neutralising antibodies against SINV. None of the samples 
were originally obtained for SINV diagnostics but taken for other pur-
poses. All serum samples were obtained through the University Animal 
Hospital in Uppsala, Sweden, coded with only date and site of sampling. 
The serum samples included in this study were taken from horses be-
tween April 18th to October 10th, 2019, from 20 regions in Sweden 
(Fig. 1). The majority of samples came from regions Uppsala and 
Stockholm. 
All samples were analysed by a SINV plaque reduction neutralisation 
test (PRNT) using a 20× serum dilution and SINV-I strain 09-M-358-5 , 
previously isolated from mosquitoes collected in central Sweden 
[14–17]. Samples, negative control (serum from a lab rabbit), positive 
control (serum from a human SINV infected patient) and virus were all 
diluted in HBSS supplemented with 2% PenStrep and 2% HEPES 
(Thermo Fischer Scientific; Vilnius, Lithuania). All sera were heat- 
inactivated at 56 ◦C for 30 min prior to testing. 
Each heat-inactivated serum sample was mixed with an equal 
amount of virus dilution and incubated at 37 ◦C for 1 h to allow any 
antibodies to react with the virus. After incubation, samples were 
inoculated in duplicates onto confluent Vero cells in a 24-well plate. Six 
wells per testing round were inoculated with the same end-dilution of 
the virus as was present in the samples, although in absence of serum. 
Cells were then incubated at 37 ◦C for 1 h to allow infection, before 
being overlaid with 1,5% Agar Noble (Sigma-Aldrich, MO, USA) which 
was mixed with equal amount of 2xMEM (supplemented with 8% FBS, 
2% Penstrep and 2% Hepes) (Thermo Fischer Scientific; Vilnius, 
Lithuania), and 1% DEAD-dextran hydrochloride (Sigma-Aldrich, MO, 
USA). The agar was allowed to stiffen before the cells were returned to 
incubate at 37 ◦C over night. 
On day two, 500 μL of 5% Neutral red solution (Sigma-Aldrich, MO, 
USA) diluted in PBS was added to each of the wells and incubated over 
night. On day three, the Neutral red was removed and all plaques were 
counted (Fig. 2). The mean number of plaques were calculated from 
each sample pair as well as from the six wells containing the virus 
control dilution. The plaque neutralisation percent was calculated as: 1- 
(mean of sample wells/mean of virus control dilution wells). 
Samples showing a high degree of neutralisation were also sequen-
tially two-fold titrated before being mixed with virus and tested as 
above, to allow determination of the end-point serum dilution required 
to neutralise the virus. 
3. Results 
SINV-PRNTs were performed on 171 serum samples collected from 
horses in 20 regions in Sweden between spring and autumn, 2019 
(Fig. 1). The measured plaque reduction ranged between 0 and 99% 
(Table 1), with six horses having serum that reduced SINV plaques 80% 
or more (≥PRNT80). End-point titration of these samples showed that 
the maximum serum dilution for ≥PRNT80 was 40×. 
Four of the six horses with ≥PRNT80 were collected in early summer, 
while two were collected in mid/late-summer. Three of the horses were 
sampled in regions previously known to be highly-endemic for SINV 
(Värmland, Dalarna, Västernorrland), while three were sampled in other 
regions (Table 2). 
4. Discussion 
In this study we detected high reduction of SINV-I (≥PRNT80) in 
serum from six horses in Sweden, indicating a preceding SINV infection. 
Previously, SINV-I infection in horses has been reported from South 
Africa, where SINV RNA was detected in the brains of horses showing 
neurological symptoms [11]. South African SINV-I strains are closely 
related to SINV-I strains that are endemic in some parts of Sweden, 
indicated by high infection rates in mosquitoes (3.6% of the Culex 
population carrying the virus in some years) and high antibody preva-
lence in passerine birds (reaching 78% in some species) [14,15]. Clearly 
SINV-I is commonly transmitted between bird-biting mosquitoes and 
birds in these regions, but tangential transmission to alternative hosts, 
such as humans and horses, is less described and understood. 
Another report of SINV neutralising antibodies in one horse and one 
donkey, originates from Australia where two other SINV genotypes 
circulate (SINV-II and SINV-VI) [5]. The authors used Whataroa virus for 
their assays, which is the same as SINV genotype V, detected only in New 
Zealand, but they do not exclude it might have been a reaction to the 
SINV genotypes circulating in Australia. Niklasson et al. [16] showed 
that such cross-reactions from antisera between different SINV geno-
types can occur. Thus, it is possible that several SINV genotypes may 
cause infection in horses. 
Reported cases of human SINV infection in Sweden are very few, 
usually ranging between none and ten per year [18]. In some years, 
however, the number of human cases increase; e.g. 60 cases were 
diagnosed in the small town of Lövånger in Västerbotten in 2012 [19]. 
Significant yearly variations in virus prevalence are also evident from 
virus detection in the mosquito vector population and from the antibody 
prevalence in the bird population [14,18]. Thus, in addition to sporadic 
cases, local outbreaks of SINV disease can occur, similar to many other 
arboviruses [20,21]. Factors affecting the risk of SINV outbreaks in 
humans or horses are so far unknown. 
The sampling location of some of the ≥PRNT80 horses (e.g. Krono-
berg), are south of the previously established main endemic region for 
Fig. 1. Sampling regions of horses analysed for neutralising antibodies against 
SINV. Circles show number of horses sampled in that region. Regions where 
horses had a titer of neutralising antibodies of 80% or more (≥PRNT80) are 
written out for comparison with Table 2. 
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SINV in Sweden [9]. Human disease cases and antibodies against SINV 
have been detected also in southern Sweden, although at a lesser extent, 
thus transmission in these regions may be less intense but is not sur-
prising. Further, any travel history of the horses has not been docu-
mented in this study and therefore sampling location is not necessary 
equal to where infection took place. 
As this is, to our knowledge, the first study specifically conducted on 
SINV serology in horses, we present the whole scale of plaque reduction 
in Table 1. Without a deeper investigation into clinical symptoms a well- 
defined threshold of reduction that defines specific SINV neutralisation 
cannot yet be established. This clinical connection would need to 
include both the time of sampling and the clinical history of the horses, 
as the duration of the antibody response is unknown. In humans, Vene 
et al. [22]. show that patients developed IgM during the first two weeks 
after onset of symptoms, and IgG antibodies two to four weeks after 
onset of symptoms. In human patients, it has been shown that antibodies 
of both IgM and IgG class can neutralise SINV [17]. In human patients 
both IgM and IgG, as well as neutralising antibodies have been detected 
up to three to four years post infection [17,22]. In horses, studies on 
antibody kinetics of other alphaviruses show that IgM antibodies against 
RRV can sometimes be detected whilst the horses display symptoms, and 
neutralising antibodies against GV can be detected six days post infec-
tion [7,23,24]. IgG antibodies against RRV were still high five weeks 
after the onset of symptoms and neutralising antibodies against GV 
remained at high levels six months after infection [7,23,24]. Thus, the 
neutralising antibodies detected in the present study could have been 
produced either from relatively new infections or from infections taking 
place in previous seasons. As for most arboviruses the highest 
Fig. 2. Wells of Vero cells showing plaques of dead cells, i.e. not stained by the red colour, caused by SINV. The two wells on the top row are duplicates of a sample 
reducing the number of plaques ≥80%. while the two wells on the bottom row are duplicates of a sample with <50% plaque reduction. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this article.) 
Table 1 
Reduction of SINV plaques by horse serum samples collected in Sweden 2019, as 
compared to the virus dilution control.  
Plaque reduction percent No. of horses Percent of total horses tested 
0–9 7 4% 
10–19 3 2% 
20–29 13 8% 
30–39 25 15% 
40–49 39 23% 
50–59 45 26% 
60–69 29 17% 
70–79 4 2% 
80–89 4 2% 
90–99 2 1% 
Total 171   
Table 2 
Sampling date and location of horses that reduced SINV plaques ≥80%. All 
















April 14 13 – 1 18 April, 
Värmland 
May 18 17 1 – 15 May, 
Västernorrland 
June 34 33 1 – 10 June, 
Uppsala 




August 38 37 – 1 12 August, 
Dalarna 
September 12 12 – – NA 
October 1 1 – – NA 
NA: Not Applicable. 
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transmission intensity of SINV occurs after late July. However, hatchling 
birds have been found with SINV antibodies on June 21st, indicating 
occurrence of SINV transmission also earlier in the season, at least 
among birds [14]. 
Plaque neutralisation tests are the gold standard in serology, and are 
often used to confirm positive results from screening assays such as 
ELISAs, immunofluorescence and immunoblotting assays [25]. ELISA 
systems are often prone to cross-reactions between closely related vi-
ruses, but are much less labour intensive than neutralisation tests. Un-
specific reactions are common in all laboratory testing systems, and 
therefore neutralisation tests often have a cut off value of 50%, 80% or 
90% reduction in plaque count to define virus specific neutralisation 
[25–27]. Previous studies on SINV neutralising antibodies in humans 
and birds have used an 80% reduction as cut-off [14,16,17,28]. In our 
study, plaque reduction varied between 0 and 99%, with half of the sera 
reducing plaques 40–60% (Table 1). No other alphavirus is known to 
infect horses in Sweden, thus sera reducing plaques more than 80% have 
very likely been infected with SINV, although no conclusions on 
development of disease can be drawn from this study. The other arbo-
viruses known to be present in Sweden are flaviviruses and orthobu-
nyaviruses, which would not cross-react in a SINV PRNT [28,29]. Tick- 
borne encephalitis virus (TBE) is known to cause infection in horses, but 
is not routinely tested for in Swedish horses since the connection to 
disease is poorly understood [30]. Other flaviviruses that circulate in 
central and southern Europe and known to cause infection in horses are 
WNV and Usutu virus (USUV), but reports of these viruses from Sweden 
are very few [31,32] and it is not established whether they are circu-
lating in the country [13]. 
As with most arboviruses, horses and humans are believed to be 
dead-end hosts of the virus, meaning that they cannot produce high 
enough viremias in their blood to infect new mosquitoes. However, very 
few studies have actually investigated the viremias in humans and 
horses and compared them with mosquito infection requirements. In this 
study we show that horses in Sweden have neutralising antibodies 
against SINV-I, which suggests for an increased awareness of the po-
tential of SINV caused disease in horses. In addition, if horses are 
commonly infected with SINV without developing disease they may be 
utilized as sentinels for epidemic transmission outside the usual bird- 
mosquito-bird transmission cycle. 
Funding 
This work was supported by The Swedish Society for Medical 
research, the Carl Trygger foundation, and the European Union‘s Hori-
zon 2020 research and innovation programme under grant No. 874735 
(VEO). 
Author’s contribution 
All authors have read and commented on the manuscript. 
Competing interest 
The authors declare that they have no competing interest. 
Acknowledgements 
The authors are grateful to all horse owners, veterinarians and lab 
staff for providing samples, and to Åke Lundkvist and Bengt Rönnberg 
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